Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04632225 · ClinicalTrials.gov registry record · Phase 2
Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Helixmith Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT04632225 is a Phase 2 study of Amyotrophic Lateral Sclerosis that has completed, run by Helixmith Co.. The registered enrollment target is 18 participants, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT04632225, a Phase 2 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Helixmith Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study was to evaluate the safety of intramuscular administration of Engensis in Participants with Amyotrophic Lateral Sclerosis as compared to Placebo. Safety will be assessed by incidences of treatment-emergent adverse events, treatment-emergent serious adverse events, injection site reactions and other adverse events of special interest, and the clinically significant laboratory values after injections of Engensis compared to Placebo. Exploratory endpoints include assessment of muscle function using the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale subscores for Fine and Gross Motor Function; muscle strength by quantitative testing using handheld dynamometry and the Accurate Test of Limb Isometric Strength where available; quality of life using the Amyotrophic Lateral Sclerosis Assessment Questionnaire-40; patient global impression of change, clinical global impression of change, and clinical global impression of severity; and evaluation of lung function using Slow Vital Capacity. Muscle biopsies will be performed during the study for future biomarker analyses.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Engensis
Study Locations (5)
Arizona
- St. Joseph's Hospital and Medical Center, Barrows Neurological Institute - Phoenix
Illinois
- Northwestern University - Chicago
Maryland
- Johns Hopkins University Department of Neurology - Baltimore
Texas
- Austin Neuromuscular Center - Austin
Other
- Hanyang University Medical Center - Seoul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-03-09 |
| Est. Completion | 2024-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04632225
The ClinicalTrials.gov registry entry for NCT04632225 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (98% lower). The listed sponsor is Helixmith Co., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04632225 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arizona, Illinois, Maryland.
Frequently Asked Questions
What is clinical trial NCT04632225 about?
NCT04632225 is a clinical study titled "Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis". The purpose of this study was to evaluate the safety of intramuscular administration of Engensis in Participants with Amyotrophic Lateral Sclerosis as compared to Placebo. Safety will be assessed by incidences of treatment-emergent adverse events, treatment-emergent serious adverse events, injection...
What is the current status of trial NCT04632225?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2021-03-09. Estimated completion is 2024-07-15.
What conditions does trial NCT04632225 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT04632225?
The interventions under investigation include: Placebo (OTHER), Engensis (BIOLOGICAL).
Who is sponsoring clinical trial NCT04632225?
This trial is sponsored by Helixmith Co., which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04632225 being conducted?
This trial has 5 study locations across Arizona, Illinois, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.